Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children
Highlights • Adjuvanted (aTIV) and two non-adjuvanted (TIV) vaccines compared in young children. • Enhanced antibody response to aTIV against all homologous and heterologous strains. • Significantly faster (after one dose) and more persistent response to aTIV. • aTIV increasingly superior to TIV wit...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2014-10, Vol.32 (46), p.6146-6156 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 6156 |
|---|---|
| container_issue | 46 |
| container_start_page | 6146 |
| container_title | Vaccine |
| container_volume | 32 |
| creator | Nolan, Terry Bravo, Lulu Ceballos, Ana Mitha, Essack Gray, Glenda Quiambao, Beatriz Patel, Sanjay S Bizjajeva, Svetlana Bock, Hans Nazaire-Bermal, Nancy Forleo-Neto, Eduardo Cioppa, Giovanni Della Narasimhan, Vas |
| description | Highlights • Adjuvanted (aTIV) and two non-adjuvanted (TIV) vaccines compared in young children. • Enhanced antibody response to aTIV against all homologous and heterologous strains. • Significantly faster (after one dose) and more persistent response to aTIV. • aTIV increasingly superior to TIV with increasing HI threshold titer. • Higher reactogenicity of aTIV, offset by increased immunogenicity. |
| doi_str_mv | 10.1016/j.vaccine.2014.08.068 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1610761518</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0264410X14012262</els_id><sourcerecordid>1610761518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-b84304e37934205c1184f705a6012bd65f4f4bcb56e93162a52ece09d348c57e3</originalsourceid><addsrcrecordid>eNqFks9u1DAQxiMEotvCI4AiIaReEvw_zgWEqhaQijgAEjfLcSa7XrL21k5WCu_DlYfgyXDYlEq9cLI8_s3nmfkmy55hVGKExattedDGWAclQZiVSJZIyAfZCsuKFoRj-TBbISJYwTD6dpKdxrhFCHGK68fZCeGEUCLEKvt56TbaGWhz7dp8DyHaOIAb0nWwjW-nPEDcexch12ttXRzyjd_53q_9GP_mbGCAcBuIQ5ihHHpr7JBUmynX-ccrXv_-Veh2Ox6Sbgpb1_UjuB86X7pIkTmYXo-qkx_dOjcb27cB3JPsUaf7CE-X8yz7enX55eJ9cf3p3YeLt9eFYZUcikYyihjQqqaMIG4wlqyrENcCYdK0gnesY41puICaYkE0J2AA1S1l0vAK6Fl2ftTdB38zQhzUzkYDfa8dpPYUFhhVAqfpJvTFPXTrx-BSdTNFJeaiEoniR8oEH2OATu2D3ekwKYzU7KPaqmUCavZRIamSjynv-aI-Njto_2XdGpeAlwugo9F9F5KJNt5xUjLGCE_cmyMHaWwHC0FFY2E23AYwg2q9_W8pr-8pmN46mz79DhPEu65VJAqpz_PSzTuHWRo6EYT-AZGN1f8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1613815676</pqid></control><display><type>article</type><title>Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Nolan, Terry ; Bravo, Lulu ; Ceballos, Ana ; Mitha, Essack ; Gray, Glenda ; Quiambao, Beatriz ; Patel, Sanjay S ; Bizjajeva, Svetlana ; Bock, Hans ; Nazaire-Bermal, Nancy ; Forleo-Neto, Eduardo ; Cioppa, Giovanni Della ; Narasimhan, Vas</creator><creatorcontrib>Nolan, Terry ; Bravo, Lulu ; Ceballos, Ana ; Mitha, Essack ; Gray, Glenda ; Quiambao, Beatriz ; Patel, Sanjay S ; Bizjajeva, Svetlana ; Bock, Hans ; Nazaire-Bermal, Nancy ; Forleo-Neto, Eduardo ; Cioppa, Giovanni Della ; Narasimhan, Vas</creatorcontrib><description>Highlights • Adjuvanted (aTIV) and two non-adjuvanted (TIV) vaccines compared in young children. • Enhanced antibody response to aTIV against all homologous and heterologous strains. • Significantly faster (after one dose) and more persistent response to aTIV. • aTIV increasingly superior to TIV with increasing HI threshold titer. • Higher reactogenicity of aTIV, offset by increased immunogenicity.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2014.08.068</identifier><identifier>PMID: 25223266</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject><![CDATA[(www.clinicaltrials.gov): NCT01346592 ; Adjuvant ; Adjuvants, Immunologic - administration & dosage ; Age ; Allergy and Immunology ; Antibodies, Viral - blood ; Antibody Formation ; Applied microbiology ; Biological and medical sciences ; Child, Preschool ; Children ; Female ; Fluad ; Fundamental and applied biological sciences. Psychology ; Hemagglutination Inhibition Tests ; Humans ; Immunogenicity ; Infant ; Infants ; Infections ; Influenza ; Influenza A Virus, H1N1 Subtype ; Influenza A Virus, H3N2 Subtype ; Influenza B virus ; Influenza vaccine ; Influenza Vaccines - administration & dosage ; Influenza Vaccines - therapeutic use ; Influenza, Human - prevention & control ; Male ; MF59 ; Microbiology ; Polysorbates - administration & dosage ; Single-Blind Method ; Squalene - administration & dosage ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Subunit - administration & dosage ; Vaccines, Subunit - therapeutic use ; Viral infections]]></subject><ispartof>Vaccine, 2014-10, Vol.32 (46), p.6146-6156</ispartof><rights>Elsevier Ltd</rights><rights>2014 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Oct 21, 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-b84304e37934205c1184f705a6012bd65f4f4bcb56e93162a52ece09d348c57e3</citedby><cites>FETCH-LOGICAL-c478t-b84304e37934205c1184f705a6012bd65f4f4bcb56e93162a52ece09d348c57e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1613815676?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28844425$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25223266$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nolan, Terry</creatorcontrib><creatorcontrib>Bravo, Lulu</creatorcontrib><creatorcontrib>Ceballos, Ana</creatorcontrib><creatorcontrib>Mitha, Essack</creatorcontrib><creatorcontrib>Gray, Glenda</creatorcontrib><creatorcontrib>Quiambao, Beatriz</creatorcontrib><creatorcontrib>Patel, Sanjay S</creatorcontrib><creatorcontrib>Bizjajeva, Svetlana</creatorcontrib><creatorcontrib>Bock, Hans</creatorcontrib><creatorcontrib>Nazaire-Bermal, Nancy</creatorcontrib><creatorcontrib>Forleo-Neto, Eduardo</creatorcontrib><creatorcontrib>Cioppa, Giovanni Della</creatorcontrib><creatorcontrib>Narasimhan, Vas</creatorcontrib><title>Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Highlights • Adjuvanted (aTIV) and two non-adjuvanted (TIV) vaccines compared in young children. • Enhanced antibody response to aTIV against all homologous and heterologous strains. • Significantly faster (after one dose) and more persistent response to aTIV. • aTIV increasingly superior to TIV with increasing HI threshold titer. • Higher reactogenicity of aTIV, offset by increased immunogenicity.</description><subject>(www.clinicaltrials.gov): NCT01346592</subject><subject>Adjuvant</subject><subject>Adjuvants, Immunologic - administration & dosage</subject><subject>Age</subject><subject>Allergy and Immunology</subject><subject>Antibodies, Viral - blood</subject><subject>Antibody Formation</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Female</subject><subject>Fluad</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hemagglutination Inhibition Tests</subject><subject>Humans</subject><subject>Immunogenicity</subject><subject>Infant</subject><subject>Infants</subject><subject>Infections</subject><subject>Influenza</subject><subject>Influenza A Virus, H1N1 Subtype</subject><subject>Influenza A Virus, H3N2 Subtype</subject><subject>Influenza B virus</subject><subject>Influenza vaccine</subject><subject>Influenza Vaccines - administration & dosage</subject><subject>Influenza Vaccines - therapeutic use</subject><subject>Influenza, Human - prevention & control</subject><subject>Male</subject><subject>MF59</subject><subject>Microbiology</subject><subject>Polysorbates - administration & dosage</subject><subject>Single-Blind Method</subject><subject>Squalene - administration & dosage</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Subunit - administration & dosage</subject><subject>Vaccines, Subunit - therapeutic use</subject><subject>Viral infections</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFks9u1DAQxiMEotvCI4AiIaReEvw_zgWEqhaQijgAEjfLcSa7XrL21k5WCu_DlYfgyXDYlEq9cLI8_s3nmfkmy55hVGKExattedDGWAclQZiVSJZIyAfZCsuKFoRj-TBbISJYwTD6dpKdxrhFCHGK68fZCeGEUCLEKvt56TbaGWhz7dp8DyHaOIAb0nWwjW-nPEDcexch12ttXRzyjd_53q_9GP_mbGCAcBuIQ5ihHHpr7JBUmynX-ccrXv_-Veh2Ox6Sbgpb1_UjuB86X7pIkTmYXo-qkx_dOjcb27cB3JPsUaf7CE-X8yz7enX55eJ9cf3p3YeLt9eFYZUcikYyihjQqqaMIG4wlqyrENcCYdK0gnesY41puICaYkE0J2AA1S1l0vAK6Fl2ftTdB38zQhzUzkYDfa8dpPYUFhhVAqfpJvTFPXTrx-BSdTNFJeaiEoniR8oEH2OATu2D3ekwKYzU7KPaqmUCavZRIamSjynv-aI-Njto_2XdGpeAlwugo9F9F5KJNt5xUjLGCE_cmyMHaWwHC0FFY2E23AYwg2q9_W8pr-8pmN46mz79DhPEu65VJAqpz_PSzTuHWRo6EYT-AZGN1f8</recordid><startdate>20141021</startdate><enddate>20141021</enddate><creator>Nolan, Terry</creator><creator>Bravo, Lulu</creator><creator>Ceballos, Ana</creator><creator>Mitha, Essack</creator><creator>Gray, Glenda</creator><creator>Quiambao, Beatriz</creator><creator>Patel, Sanjay S</creator><creator>Bizjajeva, Svetlana</creator><creator>Bock, Hans</creator><creator>Nazaire-Bermal, Nancy</creator><creator>Forleo-Neto, Eduardo</creator><creator>Cioppa, Giovanni Della</creator><creator>Narasimhan, Vas</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20141021</creationdate><title>Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children</title><author>Nolan, Terry ; Bravo, Lulu ; Ceballos, Ana ; Mitha, Essack ; Gray, Glenda ; Quiambao, Beatriz ; Patel, Sanjay S ; Bizjajeva, Svetlana ; Bock, Hans ; Nazaire-Bermal, Nancy ; Forleo-Neto, Eduardo ; Cioppa, Giovanni Della ; Narasimhan, Vas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-b84304e37934205c1184f705a6012bd65f4f4bcb56e93162a52ece09d348c57e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>(www.clinicaltrials.gov): NCT01346592</topic><topic>Adjuvant</topic><topic>Adjuvants, Immunologic - administration & dosage</topic><topic>Age</topic><topic>Allergy and Immunology</topic><topic>Antibodies, Viral - blood</topic><topic>Antibody Formation</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Female</topic><topic>Fluad</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hemagglutination Inhibition Tests</topic><topic>Humans</topic><topic>Immunogenicity</topic><topic>Infant</topic><topic>Infants</topic><topic>Infections</topic><topic>Influenza</topic><topic>Influenza A Virus, H1N1 Subtype</topic><topic>Influenza A Virus, H3N2 Subtype</topic><topic>Influenza B virus</topic><topic>Influenza vaccine</topic><topic>Influenza Vaccines - administration & dosage</topic><topic>Influenza Vaccines - therapeutic use</topic><topic>Influenza, Human - prevention & control</topic><topic>Male</topic><topic>MF59</topic><topic>Microbiology</topic><topic>Polysorbates - administration & dosage</topic><topic>Single-Blind Method</topic><topic>Squalene - administration & dosage</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Subunit - administration & dosage</topic><topic>Vaccines, Subunit - therapeutic use</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nolan, Terry</creatorcontrib><creatorcontrib>Bravo, Lulu</creatorcontrib><creatorcontrib>Ceballos, Ana</creatorcontrib><creatorcontrib>Mitha, Essack</creatorcontrib><creatorcontrib>Gray, Glenda</creatorcontrib><creatorcontrib>Quiambao, Beatriz</creatorcontrib><creatorcontrib>Patel, Sanjay S</creatorcontrib><creatorcontrib>Bizjajeva, Svetlana</creatorcontrib><creatorcontrib>Bock, Hans</creatorcontrib><creatorcontrib>Nazaire-Bermal, Nancy</creatorcontrib><creatorcontrib>Forleo-Neto, Eduardo</creatorcontrib><creatorcontrib>Cioppa, Giovanni Della</creatorcontrib><creatorcontrib>Narasimhan, Vas</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nolan, Terry</au><au>Bravo, Lulu</au><au>Ceballos, Ana</au><au>Mitha, Essack</au><au>Gray, Glenda</au><au>Quiambao, Beatriz</au><au>Patel, Sanjay S</au><au>Bizjajeva, Svetlana</au><au>Bock, Hans</au><au>Nazaire-Bermal, Nancy</au><au>Forleo-Neto, Eduardo</au><au>Cioppa, Giovanni Della</au><au>Narasimhan, Vas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2014-10-21</date><risdate>2014</risdate><volume>32</volume><issue>46</issue><spage>6146</spage><epage>6156</epage><pages>6146-6156</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Highlights • Adjuvanted (aTIV) and two non-adjuvanted (TIV) vaccines compared in young children. • Enhanced antibody response to aTIV against all homologous and heterologous strains. • Significantly faster (after one dose) and more persistent response to aTIV. • aTIV increasingly superior to TIV with increasing HI threshold titer. • Higher reactogenicity of aTIV, offset by increased immunogenicity.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>25223266</pmid><doi>10.1016/j.vaccine.2014.08.068</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2014-10, Vol.32 (46), p.6146-6156 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1610761518 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | (www.clinicaltrials.gov): NCT01346592 Adjuvant Adjuvants, Immunologic - administration & dosage Age Allergy and Immunology Antibodies, Viral - blood Antibody Formation Applied microbiology Biological and medical sciences Child, Preschool Children Female Fluad Fundamental and applied biological sciences. Psychology Hemagglutination Inhibition Tests Humans Immunogenicity Infant Infants Infections Influenza Influenza A Virus, H1N1 Subtype Influenza A Virus, H3N2 Subtype Influenza B virus Influenza vaccine Influenza Vaccines - administration & dosage Influenza Vaccines - therapeutic use Influenza, Human - prevention & control Male MF59 Microbiology Polysorbates - administration & dosage Single-Blind Method Squalene - administration & dosage Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Subunit - administration & dosage Vaccines, Subunit - therapeutic use Viral infections |
| title | Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59®-adjuvanted influenza vaccine in infants and young children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T20%3A54%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhanced%20and%20persistent%20antibody%20response%20against%20homologous%20and%20heterologous%20strains%20elicited%20by%20a%20MF59%C2%AE-adjuvanted%20influenza%20vaccine%20in%20infants%20and%20young%20children&rft.jtitle=Vaccine&rft.au=Nolan,%20Terry&rft.date=2014-10-21&rft.volume=32&rft.issue=46&rft.spage=6146&rft.epage=6156&rft.pages=6146-6156&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2014.08.068&rft_dat=%3Cproquest_cross%3E1610761518%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1613815676&rft_id=info:pmid/25223266&rft_els_id=1_s2_0_S0264410X14012262&rfr_iscdi=true |